Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE)

This study is designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNF? therapy in a UK (and Republic of Ireland) specific population.